|
1
|
Chen W, Zheng R, Zeng H, Zhang S and He J:
Annual report on status of cancer in China, 2011. Chin J Cancer
Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stein U, Walther W, Arlt F, Schwabe H,
Smith J, Fichtner I, Birchmeier W and Schlag PM: MACC1, a newly
identified key regulator of HGF-MET signaling, predicts colon
cancer metastasis. Nat Med. 15:59–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stein U, Smith J, Walther W and Arlt F:
MACC1 controls Met: What a difference an Sp1 site makes. Cell
Cycle. 8:2467–2469. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stein U, Burock S, Herrmann P, Wendler I,
Niederstrasser M, Wernecke KD and Schlag PM: Circulating MACC1
transcripts in colorectal cancer patient plasma predict metastasis
and prognosis. PLoS One. 7:e492492012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhen T, Dai S, Li H, Yang Y, Kang L, Shi
H, Zhang F, Yang D, Cai S, He Y, et al: MACC1 promotes
carcinogenesis of colorectal cancer via β-catenin signaling
pathway. Oncotarget. 5:3756–3769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang J, Chen J, Chen L, Tang J, Cui Z, Liu
C and Wang Z: Metastasis associated in colon cancer 1 (MACC1)
promotes growth and metastasis processes of colon cancer cells. Eur
Rev Med Pharmacol Sci. 20:2825–2834. 2016.PubMed/NCBI
|
|
8
|
Xie QP, Xiang C, Wang G, Lei KF and Wang
Y: MACC1 upregulation promotes gastric cancer tumor cell metastasis
and predicts a poor prognosis. J Zhejiang Univ Sci B. 17:361–366.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang T, He W, Cui F, Xia J, Zhou R, Wu Z,
Zhao Y and Shi M: MACC1 mediates acetylcholine-induced invasion and
migration by human gastric cancer cells. Oncotarget. 7:18085–18094.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang G, Fu Z and Li D: MACC1
overexpression and survival in solid tumors: A meta-analysis. Tumor
Biol. 36:1055–1065. 2015. View Article : Google Scholar
|
|
11
|
Stein U: MACC1-a novel target for solid
cancers. Expert Opin Ther Targets. 17:1039–1052. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Isella C, Mellano A, Galimi F, Petti C,
Capussotti L, De Simone M, Bertotti A, Medico E and Muratore A:
MACC1 mRNA levels predict cancer recurrence after resection of
colorectal cancer liver metastases. Ann Surg. 257:1089–1095. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang X, Yang P, Shen J, Osaka E, Choy E,
Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ and Duan Z:
Prevention of multidrug resistance (MDR) in osteosarcoma by
NSC23925. Br J Cancer. 110:2896–2904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Toden S, Okugawa Y, Jascur T, Wodarz D,
Komarova NL, Buhrmann C, Shakibaei M, Boland CR and Goel A:
Curcumin mediates chemosensitization to 5-fluorouracil through
miRNA-induced suppression of epithelialto-mesenchymal transition in
chemoresistant colorectal cancer. Carcinogenesis. 36:355–367. 2014.
View Article : Google Scholar
|
|
16
|
Toden S, Tran HM, Tovar-Camargo OA,
Okugawa Y and Goel A: Epigallocatechin-3-gallate targets cancer
stem-like cells and enhances 5-fluorouracil chemosensitivity in
colorectal cancer. Oncotarget. 7:16158–16171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Das D, Satapathy SR, Siddharth S, Nayak A
and Kundu CN: NECTIN-4 increased the 5-FU resistance in colon
cancer cells by inducing the PI3K-AKT cascade. Cancer Chemother
Pharmacol. 76:471–479. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lenz HJ: First-line combination treatment
of colorectal cancer with hepatic metastases: Choosing a targeted
agent. Cancer Treat Rev. 34 Suppl 2:S3–S7. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amiri-Kordestani L, Basseville A, Kurdziel
K, Fojo AT and Bates SE: Targeting MDR in breast and lung cancer:
Discriminating its potential importance from the failure of drug
resistance reversal studies. Drug Resist Updat. 15:50–61. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Maenhaut C, Dumont JE, Roger PP and van
Staveren WC: Cancer stem cells: A reality, a myth, a fuzzy concept
or a misnomer? An analysis. Carcinogenesis. 31:149–58. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao M, Luo R, Liu Y, Gao L, Fu Z, Fu Q,
Luo X, Chen Y, Deng X, Liang Z, et al: miR-3188 regulates
nasopharyngeal carcinoma proliferation and chemosensitivity through
a FOXO1-modulated positive feedback loop with
mTOR-p-PI3K/AKT-c-JUN. Nat Commun. 7:113092016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: Effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
